KEGG   ORTHOLOGY: K06621
Entry
K06621                      KO                                     
Symbol
CDKN2A, P16, INK4A
Name
cyclin-dependent kinase inhibitor 2A
Pathway
map01522  Endocrine resistance
map01524  Platinum drug resistance
map04110  Cell cycle
map04115  p53 signaling pathway
map04218  Cellular senescence
map04934  Cushing syndrome
map05163  Human cytomegalovirus infection
map05166  Human T-cell leukemia virus 1 infection
map05200  Pathways in cancer
map05203  Viral carcinogenesis
map05206  MicroRNAs in cancer
map05212  Pancreatic cancer
map05214  Glioma
map05218  Melanoma
map05219  Bladder cancer
map05220  Chronic myeloid leukemia
map05223  Non-small cell lung cancer
map05225  Hepatocellular carcinoma
Disease
H00004  Chronic myeloid leukemia
H00008  Burkitt lymphoma
H00009  Adult T-cell leukemia
H00014  Non-small cell lung cancer
H00015  Malignant pleural mesothelioma
H00016  Oral cancer
H00017  Esophageal cancer
H00019  Pancreatic cancer
H00022  Bladder cancer
H00025  Penile cancer
H00036  Osteosarcoma
H00038  Melanoma
H00040  Squamous cell carcinoma
H00042  Glioma
H00046  Cholangiocarcinoma
H00047  Gallbladder cancer
H00048  Hepatocellular carcinoma
H00054  Nasopharyngeal cancer
H00055  Laryngeal cancer
H01463  Mycosis fungoides
H01464  Mantle cell lymphoma
H01508  Salivary gland cancer
H01509  Tonsillar cancer
H01513  Retinoblastoma
H01556  Meningioma
H02424  Primary central nervous system lymphoma
H02434  Diffuse large B-cell lymphoma, not otherwise specified
H02942  Melanoma-astrocytoma syndrome
Brite
KEGG Orthology (KO) [BR:ko00001]
 09140 Cellular Processes
  09143 Cell growth and death
   04110 Cell cycle
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
   04115 p53 signaling pathway
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
   04218 Cellular senescence
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
 09160 Human Diseases
  09161 Cancer: overview
   05200 Pathways in cancer
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
   05206 MicroRNAs in cancer
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
   05203 Viral carcinogenesis
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
  09162 Cancer: specific types
   05212 Pancreatic cancer
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
   05225 Hepatocellular carcinoma
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
   05214 Glioma
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
   05220 Chronic myeloid leukemia
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
   05218 Melanoma
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
   05219 Bladder cancer
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
   05223 Non-small cell lung cancer
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
  09172 Infectious disease: viral
   05166 Human T-cell leukemia virus 1 infection
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
   05163 Human cytomegalovirus infection
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
  09167 Endocrine and metabolic disease
   04934 Cushing syndrome
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
  09176 Drug resistance: antineoplastic
   01524 Platinum drug resistance
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
   01522 Endocrine resistance
    K06621  CDKN2A, P16, INK4A; cyclin-dependent kinase inhibitor 2A
Other DBs
GO: 0004861
Genes
HSA: 1029(CDKN2A)
PTR: 465021(CDKN2A)
PPS: 100975637(CDKN2A)
GGO: 101145463(CDKN2A)
PON: 100461015(CDKN2A)
PPYG: 129043706(CDKN2A)
NLE: 100586796(CDKN2A)
HMH: 116458431
SSYN: 129490314
MCC: 709988
MTHB: 126937619
MNI: 105498410(CDKN2A)
CSAB: 103219354
CATY: 105591311 105591312
PANU: 101015078 101017208
TGE: 112607787 112607790
MLEU: 105533792(CDKN2A)
RRO: 104654275(CDKN2A)
RBB: 108537054(CDKN2A)
TFN: 117098660(CDKN2A)
CANG: 105503427
CJC: 100394189(CDKN2A)
SBQ: 101038444
CIMI: 108316279(CDKN2A)
ANAN: 105715592(CDKN2A)
CSYR: 103259932
MMUR: 105874194
LCAT: 123645633
PCOQ: 105827003(CDKN2A)
OGA: 100943080
MMU: 12578(Cdkn2a)
MCAL: 110293174
MPAH: 110323545
RNO: 25163(Cdkn2a)
MCOC: 116096224
ANU: 117709131
ASYL: 127680940
MUN: 110554386
CGE: 100764983
MAUA: 101825322(Cdkn2a)
PROB: 127224935
PLEU: 114698355
MORG: 121448689(Cdkn2b)
MFOT: 126510708
AAMP: 119817628
NGI: 103730663
CPOC: 100731972
CCAN: 109701107
DORD: 105988993
DSP: 122118979
DMER: 138817585
PLOP: 125360604
NCAR: 124964288
MMMA: 107147876
ITI: 101977127
OCU: 100340625
OPI: 101531644
OCZ: 121144792
GVR: 103608706(CDKN2A)
VVP: 112911644(CDKN2A)
VLG: 121495863
NPO: 129495075
AML: 100472171
UMR: 103666989
UAH: 113260575
UAR: 123781143
ELK: 111159871
LLV: 125083919
MPUF: 101672555(CDKN2A)
MLK: 131812651
EJU: 114218214
MLX: 118018235
MANO: 123849362
NSU: 110572649
LWW: 102727854
FCA: 101089220(CDKN2A)
PYU: 121034522
PCOO: 112871737
PBG: 122475137
PVIV: 125150882
LRUF: 124525759
LGF: 123593681
AJU: 106986386
PPAD: 109255826 109255843
PLEZ: 122204933
HHV: 120223233(CDKN2A)
BTA: 616369(CDKN2A)
BIU: 109562627
BBUB: 102406311
CHX: 108636541
OAS: 114113021
BTAX: 128052529
CSUM: 138081282
ODA: 120862141
CCAD: 122452871
MREE: 136148669
OVR: 110147455
MBEZ: 129557536
CFR: 102517211
CDK: 105092872
BACU: 103012968(CDKN2A)
BMUS: 118896648
LVE: 103072667(CDKN2A)
OOR: 101276268
LALB: 132522934(CDKN2A)
GMF: 115839011
DDP: 132426682
DLE: 111163175
PCAD: 102984840
PSIU: 116756160(CDKN2A)
NASI: 112415059
ECB: 100146270
EPZ: 103543573
EAI: 106824796
MYB: 102260311(CDKN2A)
MMYO: 118667589
MLF: 102419422
MDT: 132211858
MYUM: 139021300
EFUS: 103297403
SHON: 118984061(CDKN2A)
AJM: 119065840(CDKN2A)
PHAS: 123820004
MMF: 118629860
HAI: 109374675
RFQ: 117032138
PALE: 102896422
PGIG: 120617114
RAY: 107506789(CDKN2A)
MJV: 118972765
TOD: 119231948
SARA: 101551169
SFUM: 130026434
LAV: 104845647
TMU: 101345867
ETF: 123521593
DNM: 101423556
MDO: 554242(CDKN2A)
PCW: 110201193
OAA: 100083932
TACU: 119948077
PTEX: 113448044
NSS: 113415045
PRAF: 128405017
CSAI: 133437207(cdkn2a/b)
PMRN: 116938869 116948952
LRJ: 133346557 133351890
 » show all
Reference
PMID:8259215
  Authors
Serrano M, Hannon GJ, Beach D
  Title
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
  Journal
Nature 366:704-7 (1993)
DOI:10.1038/366704a0
  Sequence
[hsa:1029]
Reference
PMID:9724636
  Authors
Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH, Peters G
  Title
The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2.
  Journal
EMBO J 17:5001-14 (1998)
DOI:10.1093/emboj/17.17.5001
  Sequence
[hsa:1029]
LinkDB

DBGET integrated database retrieval system